PrimeGen US Enters Definitive Business Combination With DT Cloud Star Acquisition Corporation

ProPhase Labs Acquires Nebula Genomics

August 11, 2021

Biotechnology

ProPhase Labs, through its newly formed subsidiary ProPhase Precision Medicine, completed the acquisition of Nebula Genomics, a privately owned whole‑genome sequencing and personal genomics company. The deal (approximately $14.6 million in a mix of cash and ProPhase common stock) will integrate Nebula’s whole genome sequencing capabilities and DTC platform into ProPhase’s CLIA-certified molecular testing laboratories to expand diagnostic and consumer genomics offerings.

Genexine Announces Merger with EPD Biotherapeutics (EPD Bio)

July 4, 2024

Biotechnology

Genexine, a clinical-stage Korean biopharmaceutical company, announced a small-scale merger with EPD Biotherapeutics (EPD Bio) to strengthen its drug development pipeline. The merger is intended to add PROTAC/bioPROTAC (bioPROTAC via EPDegTM mRNA-LNP) technology talent and expand Genexine’s R&D capabilities, with EPD Bio’s founder joining Genexine to lead R&D.

Swiss Rockets AG To Acquire Complete Genomics

February 23, 2026

Healthcare Services

Complete Genomics, a U.S.-based genomic sequencing technology company, entered into a definitive agreement to be acquired by Switzerland-based life sciences group Swiss Rockets AG. The transaction is intended to scale Complete Genomics’ innovation pipeline and diversify its manufacturing capacity, with Swiss Rockets taking 100% ownership and sole control upon closing.

Genstar Capital Makes Strategic Majority Investment in Docupace

July 23, 2024

Cloud & SaaS

Genstar Capital has made a strategic majority investment in Docupace, a Holmdel, New Jersey-based provider of cloud-based software for wealth management back-office operations. The transaction is a recapitalization that will leave FTV Capital as a minority investor and position Docupace to accelerate organic and inorganic growth of its platform.

Vizgen Acquires Ultivue (Merger to Form Combined Spatial Biology Company)

October 9, 2024

Biotechnology

Vizgen and Ultivue have merged to create a single spatial biology company that combines Vizgen’s MERFISH single-cell spatial genomics platform with Ultivue’s InSituPlex assays and STARVUE proteomic/AI capabilities. Rob Carson (former CEO of Ultivue) will serve as President and CEO of the combined Vizgen, and the transaction was completed alongside Vizgen’s Series D financing backed by investors including ARCH Venture Partners, Northpond Ventures and Tao Capital Partners.

Novartis Acquires DTx Pharma

July 17, 2023

Biotechnology

Novartis has acquired DTx Pharma, a San Diego–based preclinical biotechnology company, for an upfront payment of USD 500 million plus contingent milestone payments. The deal brings DTx's FALCON siRNA delivery platform and lead program DTx-1252 (orphan-designated for CMT1A) into Novartis to strengthen its neuroscience pipeline and xRNA capabilities.